North America Generic Drugs Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The North America generic drugs market size is expected to reach US$ 2,89,261.68 million by 2031 from US$ 2,07,725.55 million in 2024. The market is estimated to record a CAGR of 4.9% from 2025 to 2031.

Executive Summary and North America Generic Drugs Market Analysis:

The generic drugs market in North America is expanding steadily, driven by rising healthcare costs, a growing population, surging patent expirations of branded drugs, and increasing demand for affordable treatment options. The US, Canada, and Mexico are the key contributors, with the US holding the largest market share. By 2030, one in five Americans will be over 65, increasing the need for cost-effective treatments for chronic conditions such as diabetes, hypertension, and arthritis. Government support and regulatory pathways also strengthen the market. Agencies such as the US FDA have accelerated approval pathways for generic drugs, ensuring faster access without compromising safety or efficacy. This has made it easier for manufacturers to bring generics to market. Another driver is the focus on healthcare cost containment. Payers and policymakers promote the use of generics to reduce overall spending. According to the Association for Accessible Medicines, generics accounted for 90% of prescriptions dispensed in the US and 18% of drug spending in 2023. The market is also seeing increased competition and consolidation. Market players are expanding portfolios through partnerships and acquisitions to gain scale and meet rising demand.

North America Generic Drugs Market: Strategic Insights

North America Generic Drugs Market Segmentation Analysis:

Key segments that contributed to the derivation of the North America generic drugs market analysis are molecule type, indication, type, and distribution channel.

• Based on molecule type, the North America generic drugs market is segmented into antidepressants, antihistamines, analgesics, antibiotics, antivirals, diuretics, and others. The antibiotics segment held the largest share of the market in 2024.

• By indication, the North America generic drugs market is segmented into metabolic diseases, cancer, immunology, respiratory disorder, cardiovascular disorder, neurology disorder, rare diseases, and others. The cancer segment held the largest share of the market in 2024.

• Based on type, the North America generic drugs market is bifurcated into prescription and OTC drugs. The prescription segment held a larger share of the market in 2024.

• By distribution channel, the North America generic drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the market in 2024.

North America Generic Drugs Market Players Density: Understanding Its Impact on Business Dynamics

The North America Generic Drugs Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

North America Generic Drugs Market Outlook

Biosimilars are gaining prominence in the global generic drugs market, influenced by several key trends. The expiration of patents for major biologic drugs has paved the way for biosimilars, offering more affordable alternatives and contributing to reduced healthcare costs. Regulatory agencies such as the FDA and EMA have established streamlined approval processes for biosimilars, facilitating their timely market entry. This has led to increased acceptance among healthcare providers, supported by real-world evidence and successful clinical trials demonstrating their safety and efficacy. As more biologic patents expire, the market has become more competitive, prompting pharmaceutical companies to invest in biosimilar development. Additionally, biosimilars are gaining traction in emerging markets, enhancing access to essential biologic treatments at reduced costs. As per the WHO, noncommunicable diseases (NCDs), including cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes, are the leading causes of death and disability worldwide. In 2019, NCDs accounted for 41 million of the 55 million global deaths, representing 75% of all deaths that year. Furthermore, ~18 million NCD-related deaths occurred before the age of 70, with 82% of these premature deaths in low- and middle-income countries. As per the UN, the global burden of NCDs is projected to increase, with estimates suggesting that by 2050, chronic diseases will account for 86% of the 90 million deaths annually, a 90% increase in absolute numbers since 2019.

The escalating prevalence of chronic diseases underscores the critical need for effective prevention and management strategies. Biosimilars play a vital role in this context by providing cost-effective treatment options, thereby improving access to necessary therapies and alleviating the financial burden on healthcare systems and patients.

North America Generic Drugs Market Country Insights

Based on country, the North America generic drugs market comprises the US, Canada, and Mexico. The US held the largest share in 2024.

The generic drugs market in the US is experiencing strong growth, fueled by the rising burden of chronic illnesses, cancer, and infectious diseases, along with a push for affordable healthcare solutions. In 2024, ~2 million new cancer cases were diagnosed, up from 1.9 million in 2022, with ~0.61 million deaths, underscoring the urgent need for cost-effective treatments. While innovative options such as therapeutic cancer vaccines (e.g., Provenge for prostate cancer), neoantigen-based vaccines for triple-negative breast cancer, and mRNA vaccines such as autogene cevumeran for pancreatic cancer are showing promising results, with trials reporting up to 88% of patients remaining cancer-free after three years, affordability and accessibility provided by generic drugs remain vital to large-scale public health impact. Generics play a pivotal role once patents expire, making life-saving medications accessible to a broader population. The US biopharmaceutical industry, which includes generic manufacturers, is a global leader in innovation and scale. According to the Pharmaceutical Research and Manufacturers of America, in 2022, the industry generated over USUS$ 800 billion in direct output and USUS$ 1.65 trillion in total economic contribution-about 3.6% of the US economy. Also, the industry invested US$141 billion in domestic R&D, representing 78.6% of all US industry-funded medical research, and operated 1,574 facilities producing FDA-approved products under strict GMP guidelines.

North America Generic Drugs Market Company Profiles

Some of the key players operating in the market include Teva Pharmaceutical Industries Ltd, Viatris Inc, Dr. Reddy's Laboratories Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, AbbVie Inc, AstraZeneca Plc, Sanofi SA, Aurobindo Pharma Ltd, and Glenmark Pharmaceuticals Ltd, among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

North America Generic Drugs Market Research Methodology:

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations.

• Industry trade journals and other relevant publications.

• Government documents, statistical databases, and market reports.

• News articles, press releases, and webcasts specific to companies operating in the market.

Note:

All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research.

• Enhance the expertise and market understanding of the analysis team.

• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers

• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise